Inicio


Publicación

Resistencia a antibióticos de última línea en cocos Gram positivos: la era posterior a la vancomicina


Información de la publicación

Información de la publicación
Tipo de publicación

Científica

Tipología

Investigación y estudios

Medio de publicación

Impreso: Revista indexada

Resumen

New therapeutic alternatives have been developed in the last years for the treatment of multidrug-resistant Gram-positive infections. Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are considered a therapeutic challenge due to failures and lack of reliable antimicrobial options. Despite concerns related to the use of vancomycin in the treatment of severe MRSA infections in specific clinical scenarios, there is a paucity of solid clinical evidence that support the use of alternative agents (when compared to vancomycin). Linezolid, daptomycin and tigecycline are antibiotics approved in the last decade and newer cephalosporins (such as ceftaroline and ceftobiprole) and novel glycopeptides (dalvavancin, telavancin and oritavancin) have reached clinical approval or are in the late stages of clinical development. This review focuses on discussing these newer antibiotics used in the "post-vancomycin" era with emphasis on relevant chemical characteristics, spectrum of antimicrobial activity, mechanisms of action and resistance, as well as their clinical utility.

Autores

Sandra Rincón , Diana Panesso , Lorena Díaz, Lina P. Carvajal, Jinnethe Reyes, José M. Munita, César A. Arias

Registro ISSN

0120-4157

SNIES Área

Immunology and Microbiology

SNIES Categoría

Infectious Diseases

Fecha de publicación 09 de diciembre de 2014
Fecha de aceptación 09 de diciembre de 2014
Medio indexado (nombre)

Biomedica Revista del Instituto Nacional de Salud

Bases de datos donde está referenciada

Pubmed, Scielo

English information
Title

Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era

Abstract

New therapeutic alternatives have been developed in the last years for the treatment of multidrug-resistant Gram-positive infections. Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are considered a therapeutic challenge due to failures and lack of reliable antimicrobial options. Despite concerns related to the use of vancomycin in the treatment of severe MRSA infections in specific clinical scenarios, there is a paucity of solid clinical evidence that support the use of alternative agents (when compared to vancomycin). Linezolid, daptomycin and tigecycline are antibiotics approved in the last decade and newer cephalosporins (such as ceftaroline and ceftobiprole) and novel glycopeptides (dalvavancin, telavancin and oritavancin) have reached clinical approval or are in the late stages of clinical development. This review focuses on discussing these newer antibiotics used in the "post-vancomycin" era with emphasis on relevant chemical characteristics, spectrum of antimicrobial activity, mechanisms of action and resistance, as well as their clinical utility.

Keywords

Complementary therapies, Gram-positive bacterias; drug resistance, microbial; vancomycin, daptomycin, cephalosporins.

Información de apoyo a la difusión
Documentos Rincon y col, Biomedica 2014

Información de contacto

Contacto de Publicaciones